Interleukin-11 to Enter Phase III

Diving Into the Practical Applications of ctDNA in Oncology Care

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP

September 25th 2025

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

ONCOLOGY Staff

September 27th 2025

How to Discuss Death: A Conversation of Mortality in Cancer Care

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Daniel C. McFarland, DO;William Breitbart, MD

September 22nd 2025

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

$Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.$

Russ Conroy

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

Tim Cortese

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Related Content

Ariana Pelosci

September 28th 2025

Diving Into the Practical Applications of ctDNA in Oncology Care

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP

September 25th 2025

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

ONCOLOGY Staff

September 27th 2025

How to Discuss Death: A Conversation of Mortality in Cancer Care

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Daniel C. McFarland, DO;William Breitbart, MD

September 22nd 2025

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

$Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.$

Russ Conroy

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Tim Cortese